CHINA CHEMICAL & PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.05 TWD | 0.00% |
|
0.00% | -9.45% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,380 | 5,722 | 7,015 | 6,733 | 9,884 | 7,238 |
| Enterprise Value (EV) 1 | 7,745 | 8,624 | 9,480 | 8,829 | 12,184 | 10,187 |
| P/E ratio | 14.5 x | 14.9 x | 12.7 x | 13.2 x | 20.9 x | 22.5 x |
| Yield | 4.42% | 4.16% | 4.24% | 3.97% | 2.41% | 2.05% |
| Capitalization / Revenue | 0.71 x | 0.72 x | 0.86 x | 0.85 x | 1.17 x | 0.84 x |
| EV / Revenue | 1.02 x | 1.08 x | 1.16 x | 1.11 x | 1.44 x | 1.19 x |
| EV / EBITDA | 13.1 x | 13.9 x | 14.1 x | 13.1 x | 19.1 x | 19.4 x |
| EV / FCF | -61.6 x | -33.4 x | 28.3 x | 27.7 x | 240 x | -118 x |
| FCF Yield | -1.62% | -2.99% | 3.54% | 3.61% | 0.42% | -0.85% |
| Price to Book | 0.95 x | 0.97 x | 1.06 x | 0.87 x | 1.34 x | 0.97 x |
| Nbr of stocks (in thousands) | 297,253 | 297,253 | 297,253 | 297,253 | 297,253 | 297,253 |
| Reference price 2 | 18.10 | 19.25 | 23.60 | 22.65 | 33.25 | 24.35 |
| Announcement Date | 19-04-01 | 20-03-31 | 21-03-30 | 22-03-30 | 23-03-30 | 24-04-01 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7,580 | 7,970 | 8,181 | 7,949 | 8,457 | 8,575 |
| EBITDA 1 | 592.3 | 621 | 673.9 | 673.1 | 639.1 | 525 |
| EBIT 1 | 336.4 | 374.6 | 421.2 | 411.4 | 368.8 | 238.7 |
| Operating Margin | 4.44% | 4.7% | 5.15% | 5.18% | 4.36% | 2.78% |
| Earnings before Tax (EBT) 1 | 450.5 | 445.6 | 657.6 | 659.2 | 588.7 | 391.2 |
| Net income 1 | 369.9 | 384.7 | 557.4 | 517.5 | 477.5 | 322.3 |
| Net margin | 4.88% | 4.83% | 6.81% | 6.51% | 5.65% | 3.76% |
| EPS 2 | 1.244 | 1.294 | 1.860 | 1.720 | 1.590 | 1.080 |
| Free Cash Flow 1 | -125.7 | -258.1 | 335.5 | 318.3 | 50.87 | -86.11 |
| FCF margin | -1.66% | -3.24% | 4.1% | 4% | 0.6% | -1% |
| FCF Conversion (EBITDA) | - | - | 49.79% | 47.29% | 7.96% | - |
| FCF Conversion (Net income) | - | - | 60.19% | 61.51% | 10.65% | - |
| Dividend per Share 2 | 0.8000 | 0.8000 | 1.000 | 0.9000 | 0.8000 | 0.5000 |
| Announcement Date | 19-04-01 | 20-03-31 | 21-03-30 | 22-03-30 | 23-03-30 | 24-04-01 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2,364 | 2,902 | 2,464 | 2,096 | 2,300 | 2,949 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.992 x | 4.674 x | 3.657 x | 3.114 x | 3.599 x | 5.616 x |
| Free Cash Flow 1 | -126 | -258 | 336 | 318 | 50.9 | -86.1 |
| ROE (net income / shareholders' equity) | 6.49% | 6.61% | 8.9% | 7.16% | 6.3% | 4.34% |
| ROA (Net income/ Total Assets) | 2% | 2.1% | 2.2% | 2.05% | 1.8% | 1.16% |
| Assets 1 | 18,507 | 18,355 | 25,337 | 25,306 | 26,532 | 27,750 |
| Book Value Per Share 2 | 19.10 | 19.90 | 22.20 | 26.10 | 24.90 | 25.00 |
| Cash Flow per Share 2 | 2.000 | 2.370 | 3.480 | 2.860 | 1.470 | 1.500 |
| Capex 1 | 208 | 490 | 262 | 208 | 257 | 247 |
| Capex / Sales | 2.74% | 6.15% | 3.2% | 2.62% | 3.04% | 2.89% |
| Announcement Date | 19-04-01 | 20-03-31 | 21-03-30 | 22-03-30 | 23-03-30 | 24-04-01 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -9.45% | 203M | |
| +13.53% | 41.95B | |
| +22.20% | 22.53B | |
| +17.35% | 14.11B | |
| +45.62% | 12.5B | |
| -0.05% | 6.79B | |
| -9.44% | 6.75B | |
| -8.87% | 5.73B | |
| +14.55% | 5.6B | |
| +4.00% | 4.95B |
- Stock Market
- Equities
- 1701 Stock
- Financials China Chemical & Pharmaceutical Co., Ltd.
